• Print
  •  

Press Releases

Abbott Licenses Biomarkers for Use in Differentiating Aggressive from Nonaggressive Prostate Cancer -
April 17, 2012

ABBOTT PARK, Ill., April 17th, 2012 - Abbott announced today it has acquired an exclusive license for several novel biomarkers from Stanford University for use in developing a molecular diagnostic test that could satisfy a longstanding unmet medical need: differentiating aggressive from nonaggressive prostate cancer.

Abbott and Merck Collaborate to Develop Companion Diagnostic Test for Investigational Cancer Therapy - Press Release
March 06, 2012

ABBOTT PARK, Ill., March 6, 2012 — Abbott announced today that it will collaborate with Merck to evaluate the use of a FISH (fluorescence in situ hybridization)-based companion diagnostic test to aid in the development of a Merck investigational cancer therapy. FISH-based companion diagnostic tests are designed to identify specific DNA sequences to help guide physicians in determining which patients are more or less likely to benefit from a particular therapy.

Abbott Expands Agreement with GSK - Press Release
November 28, 2011

DES PLAINES, Ill., Nov. 28, 2011 — Abbott announced today that it will expand its existing agreement with GlaxoSmithKline Biologicals S.A. (GSK) to include the development of an additional companion diagnostic test in support of GSK’s cancer immunotherapy research program. Companion diagnostic tests are designed to identify specific DNA sequences to help guide physicians in determining which patients are more or less likely to benefit from a particular therapy.

Abbott Receives FDA Approval for ALK Gene Test for Lung Cancer Therapy Selection - Press Release
August 29, 2011

Simultaneous Approval of New Treatment and Companion Diagnostic Represents Significant Advance in Personalized Medicine for Patients with Non-Small-Cell Lung Cancer

FDA Clears Abbott’s Genetic FISH Panel for Leukemia Patient Prognosis - Press Release
August 22, 2011

New Test Based on FISH Technology Detects Genetic Abnormalities to Aid in the Prediction of Chronic Lymphocytic Leukemia Patient Survival

Abbott Completes Submission of New Molecular Test Intended for NSCLC Therapy Selection -
May 23, 2011

ABBOTT PARK, Ill., May 23, 2011 – Abbott today announced it filed premarket approval applications to the U.S. Food and Drug Administration and the Japanese Ministry of Health, Labour, and Welfare for a new molecular diagnostic test designed to detect abnormal gene rearrangements in non-small-cell lung cancer (NSCLC) tumors. The test is a combination product to be used with Pfizer’s crizotinib, an oral first-in class anaplastic lymphoma kinase (ALK) inhibitor.

Abbott Receives FDA Approval for Molecular Test for Hepatitis C -
May 18, 2011

ABBOTT PARK, Ill., May 18, 2011 — Abbott announced today that it has received approval from the U.S. Food and Drug Administration to market its RealTime PCR (polymerase chain reaction) test for measuring the viral load of hepatitis C (HCV), the leading cause of liver cancer in the United States.